Trial Profile
An Open-Label, Multi-Center, Multiple-Application Pharmacokinetic Study of NAFT-500 in Pediatric Subjects With Tinea Cruris and Tinea Pedis and NAFT-600 in Pediatric Subjects With Tinea Pedis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 12 Dec 2017
Price :
$35
*
At a glance
- Drugs Naftifine (Primary)
- Indications Tinea cruris; Tinea pedis
- Focus Pharmacokinetics
- Sponsors Merz Pharmaceuticals
- 28 Apr 2015 New trial record